(lp0
S'Nektar Therapeutics  Moves Lower on Volume Spike for March 17 Equities.com - 18 hours ago Nektar Therapeutics  traded on unusually high volume on Mar. 17, as the stock lost 1.34% to close at $15.50. On the day, Nektar Therapeutics saw 2.38 million shares trade hands on 8,672 trades. Considering that the stock averages only a daily&nbsp;...Nektar Therapeutics  Position Boosted by State Street Corp - The Cerbat GemStock Returns: Nektar Therapeutics  is Beating Horizon Pharma plc ... - CML News'
p1
aS"Here's What's Behind Nektar Therapeutics' 20% Move Higher Motley Fool - Mar 2, 2017 Shares of Nektar Therapeutics , a biopharmaceutical company that utilizes its proprietary intellectual property via licensing deals and through collaborations in the clinical development process to help fight cancer, autoimmune diseases ...Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results - PR Newswire Nektar Therapeutics  Loss Wider than Expected in Q4 - Yahoo Finance"
p2
aS"Technical Reports on Biotech Stocks -- Nektar Therapeutics, Seattle Genetics ... PR Newswire  - Mar 13, 2017 Pre-market, Stock-Callers.com navigates the Biotechnology space with focus on Nektar Therapeutics , Seattle Genetics Inc. , Dynavax Technologies Corp.What are Analyst's Indicators for Nektar Therapeutics , PDC Energy, Inc ... - The USA CommerceNektar Therapeutics  Shares Bought by Comerica Bank - BNB Daily "
p3
aS'Nektar Therapeutics shares fall on secondary stock offering CNBC - Oct 19, 2016 Shares of Nektar Therapeutics shed about 5 percent Wednesday after the biotech company announced a secondary offering of common stock worth more than $175 million.Public Issue of Shares Weighs on Nektar Therapeutics  - Scibility Media'
p4
aS'Nektar Therapeutics: An Undervalued Biopharmaceuticals Company With Plenty In ... Seeking Alpha - Jan 20, 2017 Topline data for three candidate drugs currently in Phase III trials  expected in 1H 2017.'
p5
aS'Nektar Therapeutics Is Attractive Ahead Of Multiple Catalysts Seeking Alpha - Dec 6, 2016 Nektar Therapeutics  has two commercial products, movantik and adynovate, partnered with AstraZeneca  and Baxter  respectively, 5 partnered drug candidates in advanced stages of clinical trial, and these two&nbsp;...'
p6
aS"Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the ... PR Newswire  - Jan 5, 2017 SAN FRANCISCO, Jan. 5, 2017 /PRNewswire/ -- Nektar Therapeutics'  President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 35th Annual J.P."
p7
aS"Nektar Therapeutics: Nektar to Webcast Presentation at Cowen and Company's ... The Wall Street Transcript - Mar 3, 2017 SAN FRANCISCO, March 2, 2017 /PRNewswire/ -- Nektar Therapeutics  announced today that its corporate presentation will be webcast at the upcoming Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017&nbsp;..."
p8
aS'Nektar Therapeutics: Nektar to Announce Financial Results for the Fourth ... The Wall Street Transcript - Feb 22, 2017 SAN FRANCISCO, Feb. 22, 2017 /PRNewswire/ -- Nektar Therapeutics  will announce its financial results for the fourth quarter and year-ended December 31, 2016, on Wednesday, March 1, 2017, after the close of U.S.What Analysts are Predicting For CDK Global, Inc. , Nektar Therapeutics ... - The USA Commerce'
p9
aS"Biotech Stocks on Investors' Radar -- Vertex Pharma, Nektar Therapeutics, CTI ... PR Newswire  - Nov 22, 2016 In today's pre-market research, Stock-Callers.com recalls the most recent performances of four Biotech companies, namely: Vertex Pharmaceuticals Inc. , Nektar Therapeutics , CTI BioPharma Corp. , and&nbsp;..."
p10
a.